VANFLYTA First FLT3 Inhibitor Approved in Japan for Patients with Newly Diagnosed FLT3-ITD Positive AML May 31, 2023
CytoMed Therapeutics Announces Research Collaboration with Cancer Treatment Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology May 18, 2023
European Commission approves Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma May 18, 2023
Coeptis Therapeutics to Acquire Allogeneic Immuno-Oncology NK Platform in Ph 1 Trials from Deverra Therapeutics April 27, 2023
Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned April 27, 2023
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA April 27, 2023
First Patient dosed in FRIDA, a Ph Ib trial with iadademstat in R/R FLT3-mutant AML patients March 31, 2023
A First Complete Bone Marrow Response in a R/R AML Patient From The Very Low Dose Arm of Its AB8939 Ph 1/2 Clinical Trial (AB18001) reported March 31, 2023
Positive Full Data Results From the Pivotal Ph 3 SIERRA Trial in Patients with Active, R/R AML announced February 28, 2023
Actinium Signs Cooperative Research and Development Agreement with NCI to Further Enhance Clinical & Non-clinical Development of Actimab-A for the Treatment of AML and Other Hematologic Malignancies February 22, 2023
Ph 3 Study of Uproleselan in R/R AML to continue to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee February 22, 2023
Final Topline Data from Successful European Ph 1 monotherapy Trial of Annamycin in R/R AML patients announced February 22, 2023
Tecartus® CAR T-Cell Therapy Demonstrates OS Benefit In 3-Year Follow-Up Of Pivotal ZUMA-3 Trial In R/R B-Cell Acute Lymphoblastic Leukemia February 22, 2023
2023 EBMT-EHA: Encouraging initial safety and efficacy data for point-of-care manufactured GLPG5201 CAR-T in rrCLL presented February 22, 2023
Successful Dosing of Final Patient in ACHIEVE Safety Cohort of TCB008 Trial Announced February 8, 2023
TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of CRR in R/R CLL Patients February 1, 2023
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology January 17, 2023